Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase... Adv Ther (2017) 34:2625–2637 DOI 10.1007/s12325-017-0642-4 ORIGINAL RESEARCH Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies . . . Tomohiro Kusawake James J. Keirns Donna Kowalski . . . Martin den Adel Dorien Groenendaal-van de Meent Akitsugu Takada Yoshiaki Ohtsu Masataka Katashima Received: September 20, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication Amenamevir was administered orally at various ABSTRACT doses as a single dose (5–2400 mg) or daily (300 or 600 mg/day) for 7 days. Introduction: Amenamevir (ASP2151) is a Results: Following single and multiple oral nonnucleoside antiherpesvirus compound doses, amenamevir demonstrated a less than available for the treatment of varicella–zoster dose proportional increase in the pharmacoki- virus infections. In this article we summarize netic parameters area under the plasma drug the findings of four phase 1 studies in healthy concentration versus time curve from time zero participants. to infinity (AUC ) and C . After single and inf max Methods: Four randomized phase 1 studies multiple oral 300-mg doses of amenamevir, no investigated the safety and pharmacokinetics of apparent differences in pharmacokinetics were single and multiple doses of amenamevir, observed between http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies

Loading next page...
 
/lp/springer_journal/pharmacokinetics-and-safety-of-amenamevir-in-healthy-subjects-analysis-ncuymV0ZiB
Publisher
Springer Healthcare
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-017-0642-4
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2017) 34:2625–2637 DOI 10.1007/s12325-017-0642-4 ORIGINAL RESEARCH Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies . . . Tomohiro Kusawake James J. Keirns Donna Kowalski . . . Martin den Adel Dorien Groenendaal-van de Meent Akitsugu Takada Yoshiaki Ohtsu Masataka Katashima Received: September 20, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication Amenamevir was administered orally at various ABSTRACT doses as a single dose (5–2400 mg) or daily (300 or 600 mg/day) for 7 days. Introduction: Amenamevir (ASP2151) is a Results: Following single and multiple oral nonnucleoside antiherpesvirus compound doses, amenamevir demonstrated a less than available for the treatment of varicella–zoster dose proportional increase in the pharmacoki- virus infections. In this article we summarize netic parameters area under the plasma drug the findings of four phase 1 studies in healthy concentration versus time curve from time zero participants. to infinity (AUC ) and C . After single and inf max Methods: Four randomized phase 1 studies multiple oral 300-mg doses of amenamevir, no investigated the safety and pharmacokinetics of apparent differences in pharmacokinetics were single and multiple doses of amenamevir, observed between

Journal

Advances in TherapySpringer Journals

Published: Nov 13, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off